The Egyptian Drug Authority has issued warnings against the circulation of several biopharmaceuticals, including Atorstat 10mg F.C.T and EPOETIN 4000IU, due to reported cases of commercial fraud. The authority has confirmed that there have been instances of counterfeit versions of these medications in the market. As a result, the authority is urging caution and advising individuals to verify the source of these medications before purchasing or using them.
The warning for Atorstat 10mg F.C.T was issued due to reported cases of commercial fraud associated with this medication. Atorstat 10mg is used to lower cholesterol and triglyceride levels, as well as reduce the risk of heart disease. Meanwhile, EPOETIN 4000IU is used to treat certain cases of anemia, particularly those related to chronic kidney failure.
In addition to Atorstat 10mg F.C.T and EPOETIN 4000IU, the Egyptian Drug Authority has also warned against the potential presence of unlicensed versions of Retatrutide Injection. The authority has stated that there is a possibility of unidentified source vials or prefilled pens of Retatrutide Injection in the market.
Retatrutide Injection is an investigational medication that is currently being studied for the treatment of obesity and type 2 diabetes. However, it has not yet received the necessary regulatory approvals for commercial distribution. The authority's warning is limited to specific batches of these medications and does not apply to the medications as a whole.
The Egyptian Drug Authority's warnings are part of its efforts to enhance oversight of pharmaceutical and biopharmaceutical products, ensure their safety and efficacy, and prevent commercial fraud. The authority is working to prevent the circulation of unlicensed or counterfeit medications in the Egyptian market.
The authority has urged citizens and pharmacists to purchase medications only from licensed pharmacies and to avoid dealing with unidentified or untrusted sources. If there are any doubts about a particular medication or suspicions of counterfeit versions, individuals are advised to consult the Egyptian Drug Authority.
These warnings demonstrate the Egyptian Drug Authority's commitment to protecting public health and safety by ensuring that only authorized and safe medications are available in the market. The authority continues to monitor the situation and take necessary actions to prevent the distribution of unauthorized medications.
Key points
- The Egyptian Drug Authority warns against three biopharmaceuticals due to reported cases of commercial fraud.
- The affected medications include Atorstat 10mg F.C.T, EPOETIN 4000IU, and Retatrutide Injection.
- The authority advises individuals to verify the source of medications before purchasing or using them and to purchase only from licensed pharmacies.
